ID | 1248 |
Name of the vaccine | GSK2202083A |
Microbe | Bacteria |
Disease name | Diphtheria |
Name of bacteria | Corynebacterium diphtheriae |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 12 to 18 months |
Description of the vaccine | GlaxoSmithKline Biologicals GSK2202083A vaccine. |
Name of the manufacturer | GlaxoSmithKline |
Name of the manufacturing country | Poland |
Year of manufacture | 2010 |
Clinical Phase status | Clinical - Phase 2 |
Bacterial strain | Gram-positive bacillus. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses and a booster. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For acellular pertussis, poliomyelitis, tetanus, hepatitis B and haemophilus influenzae type b. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination (4 doses) |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT01171989 |
Reference | https://www.clinicalstudydatarequest.com/Posting.aspx?ID=136&GroupID=DEFAULT |
Other name | NA |
Additional Links | NA
|